Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Posted on by sciencefather

Prof. Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Prof. Zhirong Tan  , Xiangya Hospital, Central South University , China

Professor Zhirong Tan is a leading Chinese expert in pharmacogenomics and clinical pharmacology. Currently a professor at Xiangya Hospital, Central South University, he also serves as the Director of the Pharmacogenetics and Pharmacokinetics Research Laboratory and Deputy Director of the Drug Analysis Center. He has been instrumental in over 300 clinical trials, pushing forward the frontiers of precision medicine, especially in colorectal cancer and Alzheimer’s disease. With over 20 SCI papers, multiple patents, and co-authorship of four books, he’s widely recognized for his work in pharmacokinetics and biomarker discovery. A national GCP and GMP inspector, Prof. Tan actively contributes to pharmaceutical regulation and innovation in China. His academic and industry partnerships reflect a robust foundation in translational research and real-world drug development.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Prof. Zhirong Tan has made outstanding contributions to clinical pharmacology, pharmacogenetics, and metabolomics over two decades. His research has provided critical insights into drug metabolism, biomarker discovery, and precision medicine, especially in colorectal cancer and Alzheimer’s disease.

  2. Prolific Publication Record
    With over 22 SCI-indexed publications (first or corresponding author) and 6 CSCD papers, Prof. Tan’s research has achieved over 3550 citations and an H-index of 33 on Web of Science—evidence of the high impact and recognition of his work.

  3. Strong National & Industry Collaborations
    He has participated in or led 300+ clinical trials and secured 5 “Million+” industry-funded projects, reflecting strong ties with both academia and industry. His leadership in national-level projects, such as the “Major New Drug Development” program, showcases his influence in China’s healthcare innovation.

  4. Intellectual Property and Innovation
    With 3 granted patents and 3 under review, Prof. Tan’s ability to translate research into practical applications is evident. His individualized esomeprazole dosing regimen highlights innovation at the clinical level.

  5. Regulatory & Policy Contributions
    As a national GCP/GMP inspector, he plays a pivotal role in drug trial ethics and compliance in China. He also holds leadership roles in pharmacogenomics committees, further demonstrating his commitment to public health advancement.

  6. Academic Mentorship and Editorial Work
    In addition to research, Prof. Tan contributes as a journal reviewer, co-author of four textbooks, and mentor to the next generation of scientists, reinforcing his role as a thought leader in the field.

🔍 Areas for Improvement:

  1. International Visibility
    While Prof. Tan’s national presence is remarkable, further international collaborations, invited keynotes at global conferences, or leading roles in global consortia could enhance his visibility and expand the influence of his work.

  2. Broader Publication Range
    Publishing more frequently in top-tier international journals (e.g., Nature, The Lancet, NEJM) would increase the global academic reach of his findings.

  3. Open Science & Data Sharing
    As the field moves toward transparency, incorporating open-access publications and shared data repositories could boost both reproducibility and citations.

🎓 Education:

Professor Zhirong Tan obtained his Ph.D. from Central South University, a premier Chinese institution, where he laid the groundwork for his expertise in clinical pharmacology and pharmacogenomics. He later pursued postdoctoral research at the School of Pharmacy, University of Maryland, Baltimore, one of the top pharmaceutical research institutions in the United States. This international experience enabled him to gain a global perspective in drug metabolism, biomarker identification, and translational pharmacology. His academic training focused on cutting-edge methodologies such as metabolomics, pharmacokinetics, and precision medicine. Through continuous education and research, he has built a reputation as a highly skilled pharmacologist whose work bridges basic research and clinical applications.

💼 Experience:

With a research career spanning over two decades since 1998, Professor Zhirong Tan has led and participated in numerous national-level and provincial-level projects, including China’s National Science and Technology Major Projects. He currently holds multiple leadership positions at Xiangya Hospital, Central South University. Over the years, he has completed major research grants from NSFC, the Hunan Province, and the Ministry of Science and Technology. As a GCP and GMP inspector, Prof. Tan has overseen more than 300 clinical trials, ensuring drug development meets regulatory and ethical standards. His experience also extends to industry collaboration, with successful execution of 5 “Million+” funded projects and influential roles in pharma-academic alliances. A frequent peer reviewer and contributor to international journals, his work influences both the scientific community and regulatory frameworks.

🔬 Research Focus:

Professor Tan’s primary research focus lies in clinical pharmacology, pharmacogenomics, and metabolomics, particularly for colorectal cancer and Alzheimer’s disease. His work aims to identify and validate biomarkers for disease diagnosis, drug efficacy, and toxicity prediction. A major contributor to China’s “Major New Drug Development” initiative, he has developed personalized esomeprazole dosing regimens by studying genetic polymorphisms, SNPs, and microRNA interactions. His research also explores the pathogenesis of Alzheimer’s disease using metabolomic profiling, offering insights into early detection and potential therapeutics. He applies advanced bioanalytical methods to understand inter-individual variability in drug metabolism and therapeutic response. His projects have real-world clinical implications, transforming how drugs are prescribed, regulated, and monitored. Through his pioneering work, Prof. Tan contributes significantly to the evolution of precision medicine in China.

📚 Publication Top Notes:

  1. 📊 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

  2. ❤️ Gly389Arg polymorphism of β1‐adrenergic receptor and cardiovascular response to metoprolol

  3. 💊 CYP2C19 ultra-rapid metabolizer genotype affects voriconazole pharmacokinetics

  4. 🧬 HLA‐B35:01 allele as biomarker for Polygonum multiflorum–induced liver injury*

  5. 🌿 Repeated berberine administration inhibits cytochromes P450 in humans

  6. 💉 Effect of SLCO1B1 polymorphism on pharmacokinetics of nateglinide

  7. 🧪 Assessment of cytochrome P450 activity by five‐drug cocktail approach

  8. ☕ Plasma caffeine metabolite ratio linked to CYP1A2 polymorphisms

  9. 🔬 Inducibility of CYP1A2 by omeprazole associated with genetic polymorphism

  10. 🧫 Ile118Val polymorphism of CYP3A4 affects simvastatin lipid-lowering efficacy

📝 Conclusion:

Professor Zhirong Tan is a highly deserving candidate for the Best Researcher Award. His record of scientific excellence, clinical innovation, and regulatory leadership clearly positions him as a key contributor to modern pharmacology. His integrated approach—spanning basic science, clinical trials, and health policy—has had a measurable impact on patient care and drug development in China.

While there is room to further expand his global footprint, his accomplishments to date already demonstrate the caliber, commitment, and consistency expected of a world-class researcher.

Xingting Guo | Stem Cell Research | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Xingting Guo | Stem Cell Research | Best Researcher Award

Assist. Prof. Dr. Xingting Guo , Peking University Third Hospital , China

Dr. Xingting Guo is a dedicated postdoctoral fellow at the National Institute of Biological Sciences (NIBS), Beijing, where she has been working since 2018. With a strong academic foundation in biochemistry and molecular biology, her research delves into stem cell biology, cellular differentiation, and tumorigenesis using Drosophila and mouse models. Her expertise lies in integrating genetics, biochemistry, single-cell sequencing, and bioinformatics to unravel mechanisms of cell fate specification and intestinal homeostasis. Dr. Guo has co-authored several high-impact publications and has presented her research at both national and international conferences. Her contributions have significantly advanced our understanding of enteroendocrine cells (EECs), tissue identity, and inter-organ communication. Passionate and detail-oriented, she is actively contributing to biomedical sciences with a vision to translate fundamental biology into therapeutic insights. Her work is paving the way for novel treatments for metabolic diseases and cancers.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Innovative Research Focus: Dr. Guo has made pioneering contributions in stem cell biology, particularly in understanding cell fate specification, enteroendocrine diversity, and tumor suppression using Drosophila and murine models.

  2. Multidisciplinary Skillset: She integrates genetics, high-throughput sequencing, bioinformatics, organoid culture, and in vivo models, showcasing deep technical expertise.

  3. High-Impact Publications: Co-first author in multiple peer-reviewed journals, including Cell Reports, Nature Communications, and FEBS Journal.

  4. Leadership in Research: From graduate researcher to postdoctoral fellow, she has led multiple independent projects, contributing novel findings to developmental and regenerative biology.

  5. International Recognition: Regular presenter at top-tier conferences globally, including the European Drosophila Research Conference and Annual Drosophila Research Conference (USA).

  6. Research Funding: Successfully secured National Natural Science Foundation of China funding, reflecting scientific merit and recognition.

🔍 Areas for Improvement:

  1. Broader Collaboration: Expanding collaborations outside her current institute or internationally may enhance the translational reach and impact of her research.

  2. Mentorship Roles: While her research is strong, formal mentorship roles (e.g., supervising Ph.D. students) or teaching contributions could further demonstrate leadership.

  3. Clinical Translation: Though her mouse model work touches on therapeutic discovery, publishing more translational or clinical-facing studies could boost her impact in applied biomedical research.

🎓 Education:

Dr. Xingting Guo earned her Ph.D. in Biochemistry and Molecular Biology from the College of Life Sciences at Beijing Normal University (2012–2018), where she began her in-depth research on stem cell biology and tissue differentiation in Drosophila. Prior to this, she completed her Bachelor’s degree in Biological Engineering at Nanjing Agricultural University (2008–2012), where she was honored with multiple scholarships for academic excellence. Throughout her education, she developed a robust foundation in molecular biology, genetics, and developmental biology, equipping her with the skills to tackle complex biological questions. Her academic journey has been characterized by continuous academic excellence, curiosity-driven research, and a commitment to uncovering the molecular mechanisms of health and disease. Her education laid the groundwork for her successful transition to cutting-edge postdoctoral research in developmental biology and regenerative medicine.

💼 Experience:

Dr. Guo began her research career at NIBS Beijing as a graduate student in 2012, transitioning into a postdoctoral fellow in 2018 under the mentorship of Dr. Rongwen Xi. Her research primarily uses Drosophila intestinal systems and murine models to explore the regulation of cellular identity, differentiation, and plasticity. She has led multiple projects on tumor suppression, transcriptional regulation, and enteroendocrine diversity using advanced techniques like genetic manipulation, single-cell RNA sequencing, and organoid cultures. Additionally, she contributes to translational research by identifying drug targets for diabetes-related therapy by reprogramming intestinal cells into insulin-producing β-cells. Her interdisciplinary approach and long-standing expertise in stem cell biology highlight her versatility and innovation in research. Her consistent progression from graduate student to independent researcher reflects her strong scientific rigor and leadership in high-impact studies.

🏆 Awards and Honors:

Dr. Xingting Guo has been recognized for her academic excellence and scientific contributions through numerous honors. During her Ph.D., she was awarded the First Class Academic Scholarship for two consecutive years (2014–2016). As an undergraduate, she earned the prestigious Cyrus Tang Scholarship four times, along with the First Class Scholarship at Nanjing Agricultural University. In recent years, she has taken on the role of a peer reviewer for Bio-protocols, highlighting her engagement with the scientific community. Dr. Guo’s research excellence has led her to represent her work at top-tier conferences, including the Annual Drosophila Research Conference (USA) and the European Drosophila Research Conference (Switzerland). Her contributions were also supported by a grant from the National Natural Science Foundation of China (Grant No. 3210050518), demonstrating her ability to secure competitive funding. These accolades mark her as a rising star in molecular and developmental biology.

🔬 Research Focus:

Dr. Guo’s research focuses on the molecular regulation of stem cell differentiation, cellular identity maintenance, and neuroendocrine cell plasticity using Drosophila and mouse models. She investigates how transcription factors such as ttk69 influence enteroendocrine (EEC) specification, tissue homeostasis, and tumor suppression. Using cutting-edge tools like CRISPR, single-cell transcriptomics, and in vivo lineage tracing, she deciphers how intestinal stem cells differentiate into diverse terminal cell types. Her recent work explores how intestinal EECs regulate systemic physiology via neuropeptides in response to environmental cues like starvation and mating. In parallel, she studies cell-fate reprogramming in mammals to identify potential therapeutic strategies for diabetes by inducing insulin-producing cells in the gut. By bridging basic biology with translational goals, her work contributes to regenerative medicine, oncology, and metabolic disease research.

📚 Publications Top Notes:

  • 🧠 Cell-fate conversion of intestinal cells in adult Drosophila midgut by depleting a single transcription factor, Nature Communications, 2024

  • 🔍 The Specification and Function of Enteroendocrine Cells in Drosophila and Mammals: A Comparative Review, FEBS Journal, 2021

  • 🧬 A Switch in Tissue Stem Cell Identity Causes Neuroendocrine Tumors in Drosophila Gut, Cell Reports, 2020

  • 🧫 The Cellular Diversity and Transcription Factor Code of Drosophila Enteroendocrine Cells, Cell Reports, 2019

  • 🧬 Division of Labor: Roles of Groucho and CtBP in Notch-Mediated Lateral Inhibition, Stem Cell Reports, 2019

  • 📘 Signaling Pathways Regulating Stem Cells, Book Chapter, Springer, 2015

  • 🛑 Ttk69 acts as a master repressor of enteroendocrine cell specification, Development, 2015

  • 🧪 EGFR and Notch signaling regulate gastric stem cells, Cell Research, 2014

  • 🧠 Sox9 Ortholog Regulates Intestinal Homeostasis and Regeneration in Drosophila, Cell Reports, 2020

🧾 Conclusion:

Dr. Xingting Guo is a highly qualified and deserving candidate for the Best Researcher Award. Her exceptional track record in stem cell biology, cellular reprogramming, and disease modeling makes her a rising star in the life sciences. With a unique combination of technical excellence, scientific innovation, and publication strength, she has already made a significant impact on our understanding of intestinal cell biology and endocrine regulation. Addressing a few career development aspects—like expanding collaborative networks and clinical translation—will make her an even more formidable leader in the field. Given her achievements, potential, and contributions, she is strongly recommended for this prestigious honor.

Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Posted on by sciencefather

Prof. Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Raphaël Rodriguez , CNRS, Institut Curie, France

Raphaël Rodriguez, born October 27, 1978, in Avignon, France, is a pioneering chemical biologist and Research Director at CNRS, Principal Investigator at Institut Curie, and holder of the Skłodowska-Curie Chair of Chemical Biology. A French citizen with two children, Lucía del Mar and Aramis, Rodriguez is renowned for bridging chemistry and biology to unlock the molecular secrets of cancer and inflammation. Trained in the UK under legendary scientists Sir J. E. Baldwin, Sir S. Balasubramanian, and Sir S. P. Jackson, he returned to France to launch groundbreaking research on ferroptosis and metal regulation in cell adaptation. His entrepreneurial and academic excellence earned him numerous accolades, including the National Order of Merit. With more than 130 publications and several successful biotech ventures, Rodriguez continues to shape the future of medical science with bioactive molecules like Ironomycin and Pyridostatin. He is an editorial board member, reviewer, teacher, and a public voice on science.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Pioneering Scientific Impact:
    Dr. Rodriguez has contributed over 130 high-impact publications in top-tier journals like Nature, Science, JACS, Nature Chemistry, and Cell Metabolism. His work has helped define ferroptosis, a form of programmed cell death, and metal regulation in cancer—a game-changing area in molecular medicine.

  2. Innovation & Translation:
    He discovered and commercialized small molecules such as Pyridostatin, Ironomycin, and Supformin, directly impacting both science and therapeutics. His work bridges fundamental science and drug discovery.

  3. Leadership & Mentorship:
    From mentoring under renowned scientists to leading his own lab at Institut Curie, he has shaped France’s next generation of researchers in chemical biology.

  4. Recognition & Awards:
    His extensive list of prestigious awards, including the CNRS Silver Medal, Liliane Bettencourt Prize, and Knight of the National Order of Merit, reflect peer recognition on national and international levels.

  5. Entrepreneurship:
    As a co-founder of biotech companies (e.g., Adrestia Therapeutics, later acquired), he has demonstrated a rare capacity to translate discoveries into clinical and commercial value.

  6. Scientific Influence:
    Editorial board memberships and frequent invitations to over 160 major conferences show his reputation as a global thought leader in his field.

🔧 Areas for Improvement:

  1. Public Engagement Scaling:
    Although Dr. Rodriguez is active in media (radio, TV, print), expanding international science outreach (e.g., global science festivals, public lectures, social media presence) could help further democratize his scientific message.

  2. Clinical Translation:
    While several molecules from his lab are commercialized, more direct clinical trials or FDA approvals tied to his molecules would elevate his impact from bench to bedside.

  3. Collaborative Diversity:
    Encouraging more global South collaborations or mentorships could help broaden his lab’s international footprint and contribute to equitable science capacity building.

🎓 Education:

Raphaël Rodriguez’s academic journey is marked by elite training and impactful credentials across Europe. He earned his PhD in Chemistry (2002–2005) through a joint program between Marseille and Oxford. He then pursued postdoctoral research as a Senior Research Associate at Cambridge’s Department of Chemistry and Gurdon Institute (2005–2012), where he developed skills at the interface of chemistry and biology. In 2012, he obtained the prestigious Habilitation à Diriger des Recherches from the University of Paris-Saclay, enabling him to supervise PhD candidates and lead independent research. His rise through the academic ranks was rapid: he became a CNRS Group Leader in 2012, then Principal Investigator at Institut Curie in 2015. In 2017, he was promoted to Research Director (DR1) at CNRS. In 2020, he was awarded the Skłodowska-Curie Chair of Chemical Biology at Institut Curie. His interdisciplinary training under world-renowned mentors has uniquely positioned him at the forefront of chemical biology research.

💼 Experience:

Raphaël Rodriguez’s professional experience is a blend of high-level research, leadership, and innovation. He began his postdoctoral career at the University of Cambridge (2005–2012), working in the Department of Chemistry and the Gurdon Institute. In 2012, he became a CNRS Group Leader at ICSN, Gif-sur-Yvette, launching his independent research career. In 2015, he transitioned to Institut Curie as a Principal Investigator, where he deepened his focus on cancer and inflammation. His promotion to Research Director (DR1) at CNRS in 2017 reflects his impact and leadership. Awarded the Skłodowska-Curie Chair of Chemical Biology in 2020, Rodriguez oversees a productive lab that investigates ferroptosis, DNA structure, and metal ion regulation in disease. He is also an entrepreneur, co-founding Adrestia Therapeutics and OrbiThera. He teaches at PSL University, organizes international conferences, and contributes to editorial boards and scientific advisory boards worldwide, maintaining a strong presence in both academia and biotech.

🏆 Awards and Honors:

Raphaël Rodriguez has received an impressive array of honors, showcasing his impact on science and innovation. In 2024 alone, he won the CNRS Silver Medal and the Ligue Contre le Cancer Duquesne Prize. His earlier recognition includes the prestigious Liliane Bettencourt Prize for Life Sciences (2023), the Knight of the National Order of Merit (2022, presented by Nobel Laureate Jean-Marie Lehn), and the Klaus Grohe Prize (2022). He has also been awarded the Antoine Lacassagne Prize (Collège de France, 2019), the Sunrise Cancer Stem Cell Award (2019), the Charles Defforey–Institut de France Prize (2019), and the Tetrahedron Young Investigator Award (2019). Rodriguez is a Fellow of the Royal Society of Chemistry (2018) and won the Pierre Fabre Award for Therapeutic Innovation (2015). These accolades affirm his contributions across cancer research, chemical biology, and molecular therapeutics, as well as his success in translating science into societal benefit through entrepreneurship.

🔍 Research Focus:

Raphaël Rodriguez’s research lies at the cutting edge of chemical biology, with a focus on understanding how cells adapt to stress, particularly in the contexts of cancer and inflammation. His laboratory explores the role of metal ions—especially iron—as regulators of cellular plasticity and fate. Notably, his team discovered mechanisms underlying ferroptosis, a form of regulated cell death linked to iron metabolism, and how this can be exploited for anti-cancer therapies. He also investigates non-canonical DNA structures like G-quadruplexes, using small molecules to study and manipulate gene regulation. His lab has developed and commercialized several potent bioactive compounds, including Pyridostatin, Remodelin, Ironomycin, and Supformin, which are used both as research tools and potential therapeutics. Rodriguez combines molecular design, cell biology, and translational strategies, making his work a blueprint for chemical biology-driven precision medicine. He continues to raise significant research funding and actively collaborates across academia and biotech.

📚 Publications Top Notes:

  1. 🧬 Small-molecule–induced DNA damage identifies alternative DNA structures in human genes – Nature Chemical Biology

  2. ⚙️ Salinomycin kills cancer stem cells by sequestering iron in lysosomes – Nature Chemistry

  3. 🛡️ A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres – JACS

  4. 🧫 Chemical inhibition of NAT10 corrects defects of laminopathic cells – Science

  5. 🧠 The transcription factor FOXM1 is a cellular target of the natural product thiostrepton – Nature Chemistry

  6. 🧪 Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands – JACS

  7. 🔥 PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers – Cell Metabolism

  8. 🔬 A single-molecule platform for investigation of G-quadruplex interactions with small-molecule ligands – Nature Chemistry

  9. 🧲 Small-molecule-mediated G-quadruplex isolation from human cells – Nature Chemistry

  10. 🧬 CD44 regulates epigenetic plasticity by mediating iron endocytosis – Nature Chemistry

  11. 🧷 Selective RNA vs DNA G-Quadruplex Targeting by In Situ Click Chemistry – Angewandte Chemie

  12. 🧬 G-Quadruplex-Binding Benzo[a]phenoxazines Down-Regulate c-KIT Expression in Gastric Carcinoma Cells – Journal of Medicinal Chemistry

🧾 Conclusion:

Dr. Raphaël Rodriguez exhibits exceptional merit and impact across the entire research ecosystem—fundamental science, innovation, mentorship, and commercialization. His trailblazing work in chemical biology, coupled with a record of scientific leadership and entrepreneurship, makes him highly deserving of the Best Researcher Award. His career reflects a rare blend of depth, vision, and cross-disciplinary innovation. Minor enhancements in global public engagement and clinical integration could further elevate his already stellar profile.

Xueru Li | Molecular Mechanisms Signaling | Cell Microenvironment Award

Posted on by sciencefather

Ms. Xueru Li | Molecular Mechanisms Signaling | Cell Microenvironment Award

Ms. Xueru Li , Chongqing Medical University , China

Li Xueru is an accomplished researcher and scientist with expertise in clinical laboratory diagnostics. He obtained his Ph.D. in Clinical Laboratory Diagnostics from Chongqing Medical University. Xueru has contributed extensively to scientific research, particularly in the field of cell microenvironment, fibrosis, and oxidative stress. His research has involved collaborations with prestigious organizations, such as the Chongqing Education Commission and Chongqing Natural Science Foundation. Through his academic journey, he has demonstrated a strong commitment to advancing knowledge in biomedical sciences, particularly in the areas of lung fibrosis and cellular response to environmental stress. Li Xueru is an active participant in research projects and has co-authored several influential publications that have contributed to the advancement of molecular biology and clinical diagnostics.

Publication Profile:

Scopus

Strengths for the Award:

Li Xueru’s expertise in clinical laboratory diagnostics, combined with his research in the field of cell microenvironment and fibrosis, positions him as a strong candidate for the Research for Cell Microenvironment Award. His work, especially the study on “Pharmaceutical targeting of succinate dehydrogenase in fibroblasts to control bleomycin-induced lung fibrosis,” highlights his contributions to understanding cellular mechanisms in fibrosis and oxidative stress. His involvement in high-impact research funded by organizations like the Chongqing Education Commission and the Chongqing Natural Science Foundation shows a commitment to advancing scientific knowledge and contributing to both academic and practical advancements in biomedical sciences. Moreover, his ability to bridge fundamental research with clinical applications demonstrates a strength that aligns with the goals of the Research for Cell Microenvironment Award.

Areas for Improvements:

While Li Xueru’s research focus is promising, there is potential to expand his exploration of cellular microenvironment to include other disease models and extend beyond lung fibrosis. Diversifying his research topics could provide a broader understanding of cellular behavior across different tissues and disease states. Additionally, there could be more emphasis on the development of therapeutic interventions, potentially accelerating the translation of his discoveries into clinical practices. Increasing collaboration with international research teams may also offer new perspectives and further enhance the impact of his work.

Education:

Li Xueru earned his Ph.D. degree in Clinical Laboratory Diagnostics from Chongqing Medical University, one of China’s leading medical institutions. His academic background has provided him with in-depth knowledge of diagnostic technologies, clinical pathology, and molecular biology. During his doctoral studies, he developed expertise in understanding cellular behavior and disease mechanisms at the molecular level, with a particular focus on how environmental stress impacts cellular functions. This education laid the foundation for his career in the biomedical field. He has further strengthened his research skills by participating in various projects funded by the Chongqing Education Commission and the Chongqing Natural Science Foundation. His education has been instrumental in shaping his approach to scientific inquiry, fostering a comprehensive understanding of clinical diagnostics, and equipping him to lead innovative research in the cellular microenvironment and disease mechanisms.

Experience:

Li Xueru’s experience spans a wide range of research activities focused on clinical laboratory diagnostics and cell microenvironment. His involvement in multiple high-impact research projects, supported by institutions like the Chongqing Education Commission and the Chongqing Natural Science Foundation, showcases his leadership in advancing scientific knowledge. Xueru has worked closely with interdisciplinary teams to address complex problems in the biomedical field, particularly lung fibrosis and oxidative stress. His research contributions include identifying novel cellular mechanisms involved in disease pathogenesis, improving diagnostic methodologies, and exploring therapeutic strategies for disease management. He has demonstrated a remarkable ability to apply scientific research in real-world contexts, ensuring that his findings have practical applications in medical diagnostics and treatment. His collaborative approach and innovative thinking have positioned him as a key figure in his field, contributing significantly to both academic literature and clinical advancements.

Research Focus:

Li Xueru’s primary research focus revolves around the molecular mechanisms of diseases, particularly lung fibrosis and cellular responses to environmental stressors. He is dedicated to understanding the impact of oxidative stress on cellular functions and its role in disease progression. His research explores the microenvironment of cells in response to various stimuli, including chemical agents like bleomycin. A significant area of his research is the role of succinate dehydrogenase in fibroblasts and its potential as a pharmaceutical target to control lung fibrosis. Through his work, Xueru has contributed to a better understanding of how cells interact with their microenvironment, which is crucial for developing new diagnostic and therapeutic approaches. His innovative studies on cell signaling pathways, fibrosis, and oxidative stress have the potential to transform treatment strategies for diseases related to chronic inflammation and tissue fibrosis.

Publications Top Notes:

  • Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis 🧬

  • Corrigendum to “Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis” 🔬

Conclusion:

Li Xueru is a promising candidate for the Research for Cell Microenvironment Award. His significant contributions to the understanding of cellular mechanisms in fibrosis and oxidative stress have led to valuable insights into the pathophysiology of diseases. By focusing on the cell microenvironment and its role in disease progression, his work is advancing scientific knowledge with important implications for diagnostics and therapy. With further diversification of his research and expanded collaborations, Li Xueru has the potential to make even greater strides in the field, ultimately improving patient outcomes and advancing the application of his findings in clinical settings.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Posted on by sciencefather

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions 📚 – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise 🏥 – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants 💰 – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions 🏆 – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

📌 Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

🎓 Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

💼 Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

🏆 Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai 🏅

  • Shanghai Medical Leading Talent 🎖️

  • Shanghai Craftsman & Shanghai Medical Craftsman 🏆

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

🔬 Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

📚 Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel 🔬🧬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy 🏥🧪

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway 🏥💊

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer 🔎⚕️

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus 🏥🔬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma 💉🔬

  7. Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men 🧬🧑‍⚕️

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer 🩸🛡️

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma 🏥📊

🏅 Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. 🚀

Qasem Ramadan | Cell-Cell Communication | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Qasem Ramadan | Cell-Cell Communication | Best Researcher Award

Assist. Prof. Dr. Qasem Ramadan , Alfaisal University , Saudi Arabia

Dr. Qasem Ramadan is a distinguished researcher and educator, currently serving as an Assistant Professor of Research at Alfaisal University, Riyadh, Saudi Arabia. With a strong academic background in biomedical engineering and a passion for advancing alternative technologies in health care, he has significantly contributed to the development of organ-on-a-chip systems. Dr. Ramadan’s work promotes the 3Rs (Replacement, Reduction, and Refinement) in biomedical research, aiming to replace animal testing with advanced microphysiological models. With fluency in Arabic, English, and intermediate proficiency in French, Malay, and Mandarin, he brings a global perspective to his research. He is known for his dedication to mentoring students, fostering a collaborative and innovative environment.

Publication Profile:

Google Scholar

Strengths for the Award

Dr. Qasem Ramadan is an exemplary candidate for the Best Researcher Award due to his extensive expertise in bio-medical engineering, specifically in the development of advanced in vitro models such as organs-on-a-chip. His research contributions are pioneering in areas such as pharmacokinetics, toxicology, and disease modeling. Dr. Ramadan’s dedication to reducing animal testing through the application of the 3Rs (Replacement, Reduction, and Refinement) principles reflects his commitment to ethical scientific practices. His leadership in multidisciplinary research, combined with his commitment to mentoring students and fostering academic excellence, has had a profound impact on both academic and industry settings. Dr. Ramadan’s track record of high-impact publications, notable patents, and prestigious awards further supports his suitability for the award.

Areas for Improvement

While Dr. Ramadan’s accomplishments are commendable, there is room for enhancing the global visibility of his work. Engaging more actively in high-visibility international conferences and collaborations could further amplify the reach of his research. Expanding cross-disciplinary partnerships could also unlock new applications in biotechnology and healthcare, promoting more impactful translational research.

Education:

Dr. Qasem Ramadan holds a Ph.D. in Bio-Medical Microsystems from Nanyang Technological University (2006), Singapore. His doctoral research focused on the development of magnetic micro-devices for the separation and manipulation of biological components, which forms the foundation for his ongoing work in microfluidics and biomedical technology. He also earned an MSc in Medical Physics from the University of Science in Malaysia in 1999, further enhancing his expertise in the application of physics to medicine. Dr. Ramadan completed his undergraduate studies in Physics at Yarmouk University, Jordan, in 1991. His multidisciplinary educational background has enabled him to bridge the gap between physics, engineering, and medicine, contributing to significant advancements in biomedical research, particularly in organ-on-a-chip technology and biosensors.

Experience:

Dr. Ramadan’s academic career spans over two decades, with extensive experience in both research and education. Currently an Assistant Professor of Research at Alfaisal University, he leads innovative projects in biomedical engineering, particularly focusing on microfluidics and lab-on-a-chip systems. Prior to this, he has worked on numerous groundbreaking projects in biomedical devices and systems, especially in the areas of biosensors, organ-on-a-chip technology, and magnetic bead-based applications. He has collaborated with a variety of international institutions, including Nanyang Technological University, where he completed his Ph.D. His experience in academia is complemented by his leadership in mentoring students and researchers, as well as his involvement in various international committees. Through his research and leadership, Dr. Ramadan has demonstrated a strong commitment to advancing biomedical technologies and improving healthcare applications, particularly in drug development, disease modeling, and toxicology.

Awards and Honors:

Dr. Qasem Ramadan has been recognized for his contributions to the field of biomedical engineering through numerous prestigious awards. He received the Alfaisal University Faculty Award for Research Excellence in 2024, underscoring his impact on the research community. In 2023, he was honored with the Outstanding Reviewer Award from the Royal Society of Chemistry for his work in the Journal of Lab-on-a-Chip. His early career was marked by the 1st Prize Research Award for his first-author publication at the Institute of Microelectronics, Singapore, in 2006. These awards reflect his exceptional contributions to advancing microfluidics and biomedical devices. Dr. Ramadan’s recognition also extends to his editorial work, with significant contributions to high-impact journals in the field. These honors highlight his continuous dedication to advancing biomedical research and his efforts to inspire innovation in both academic and industrial contexts.

Research Focus:

Dr. Qasem Ramadan’s research focuses on developing cutting-edge in vitro micro-physiological models for human organs, specifically organ-on-a-chip technology. His research interests include in vitro disease modeling, pharmacokinetics, toxicology, and the development of biosensors and medical devices. One of his key projects involves creating a micro-physiological model to explore the role of immune-metabolic interactions in insulin resistance and Type II diabetes. He is also pioneering advancements in creating immune-competent models of human skin to study chemical and skin sensitizers and their impact on immune activation. Dr. Ramadan’s work spans several areas, including magnetic bead-based applications, microfluidics, and the development of 3D bioprinting techniques for regenerative medicine. His research aims to replace animal testing with alternative technologies, promoting the principles of the 3Rs (Replacement, Reduction, Refinement). His work has significant implications for advancing drug discovery, personalized medicine, and disease modeling.

Publications Top Notes:

  1. An Integrated and Modular Compartmentalized Microfluidic System for Organs-on-a-Chip 🧬🔬
  2. Hepatic Spheroid-on-a-Chip for Drug Screening 💊🧫
  3. NIR-FRET Imaging of MMP-2 in ALI/ARDS 📸🩺
  4. Emerging Tools Shaping Drug Discovery & Development 🔧💉
  5. Biosensing Platform for Biomarkers in ALI/ARDS 🧪🩸
  6. Innovative Approaches in Drug Discovery 💡💊
  7. Detection of Exosomal miR210 Using Carbon Nanomaterial-Coated Magnetic Beads 🧬⚙️
  8. Immunity-on-a-Chip: Integration of Immune Components 🛡️🔬
  9. Pre-concentration and Detection of Colorectal Cancer Exosomes 🧬🦠
  10. In Vitro Micro-Physiological Immune-Competent Model of the Human Skin 🌱🧪

Conclusion

In conclusion, Dr. Qasem Ramadan’s extensive research in bio-medical microsystems, particularly his contributions to organ-on-a-chip technologies, his leadership in promoting ethical research alternatives, and his impressive academic and professional accomplishments make him a highly deserving candidate for the Best Researcher Award. His work continues to shape the future of biomedical research and healthcare technologies, and his dedication to advancing alternative methods in drug discovery and disease modeling is both innovative and invaluable.

Felicia ANTOHE | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Posted on by sciencefather

Dr. Felicia ANTOHE | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Dr. Felicia ANTOHE , Inst. Cellular Biology and Pathology NS , Romania

Dr. Felicia Antohe is the Head of the Proteomics Department at the Institute of Cellular Biology and Pathology, Romanian Academy. With a background in cellular biology and biophysics, she has contributed significantly to biomedical research, particularly in vascular endothelium, atherosclerosis, diabetes, and immune disorders. She has received multiple prestigious awards and conducted pioneering research, especially on the transcytosis of macromolecules in endothelial cells. As a PhD advisor, she mentors young researchers, having guided 12 PhD students to date. Dr. Antohe is an internationally recognized expert with extensive experience in immunology, cell biology, and proteomics.

Publication Profile:

Google Scholar

Strengths for the Award:

Dr. Felicia Antohe stands out as an exceptional candidate for the Research for Molecular Cell Biology Award due to her extensive academic and research achievements. As Head of the Proteomics Department at the Institute of Cellular Biology and Pathology, Romanian Academy, her leadership in pioneering research in endothelial cell biology and vascular pathologies has been transformative. Dr. Antohe’s strong academic background, with a Master’s in Biophysics and a PhD in Cellular Biology, complements her robust research portfolio. With over 170 scientific papers, 90 of which are indexed in Web of Science, she is recognized for her contributions to molecular mechanisms in diseases such as atherosclerosis, diabetes, and immune disorders. Furthermore, her work on monoclonal antibodies and proteomics has had a significant impact on both scientific and clinical advancements.

Areas for Improvement:

While Dr. Antohe’s research is highly regarded, there is potential for greater integration of her research with cutting-edge technologies in bioinformatics and computational biology. This could further expand her work on proteomics and molecular mechanisms. Additionally, there is an opportunity for broader outreach to apply her findings in practical therapeutic contexts through collaborations with pharmaceutical companies or clinical trials. Expanding her influence in translational research could have a larger impact on public health, especially in diseases such as diabetes and cardiovascular disorders.

Education:

Dr. Felicia Antohe holds a Master’s degree in Biophysics from the University of Bucharest (1977). She completed her PhD in Cellular Biology at the Romanian Academy’s Institute of Cellular Biology and Pathology (1994). In addition to her formal education, she has been a PhD coordinator since 2000 and has contributed significantly to research training at national and international levels. Her work blends theoretical knowledge with cutting-edge lab techniques in molecular biology, proteomics, and immunology.

Experience:

Dr. Antohe’s research experience spans numerous roles. She is currently the Principal Investigator and Member of the Scientific Council at the Romanian Academy’s Institute of Cellular Biology and Pathology. She has also worked as a visiting scientist at prestigious institutions like McGill University, University of Alberta, and Max Planck Institute. She has coordinated over 44 research projects, including national and international grants, and is actively involved in multiple collaborative research efforts across Europe and beyond. Her leadership in cell biology and proteomics is widely recognized.

Awards and Honors:

Dr. Antohe has received numerous awards, including the EURESCO Prize (2001), the BIO-RAD Laboratories Prize for valuable research (2002), and the Romanian Academy Emil Racovita Prize (1991). She has also won multiple international recognitions for her scientific contributions, such as the Best Poster award at the “8th International Conference on Vascular Endothelium” (2005), and various fellowships and grants from organizations like COST and the European Science Foundation.

Research Focus:

Dr. Antohe’s research focuses on endothelial cell biology, particularly transcytosis, endocytosis, and cell receptor mechanisms in both health and disease. She investigates the bio-pathology of atherosclerosis, diabetes, and immune disorders, with particular attention to the transport of macromolecules across vascular cells. Her work also explores the role of monoclonal antibodies as diagnostic and therapeutic tools. She applies proteomic techniques to study endothelial cell function, aiming to understand vascular biology at molecular and cellular levels.

Publications Top Notes:

  • The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans 📄
  • Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice 📄
  • Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey 📄
  • Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells 📄
  • Analytical techniques for multiplex analysis of protein biomarkers 📄
  • Functional ultrastructure of the vascular endothelium: changes in various pathologies 📄
  • Effect of enoxaparin on high glucose-induced activation of endothelial cells 📄
  • Albumin-binding proteins function in the receptor-mediated binding and transcytosis of albumin across cultured endothelial cells 📄
  • Carbapenemase-Producing Klebsiella pneumoniae in Romania: A Six-Month Survey 📄
  • Establishment of a pure vascular endothelial cell line from human placenta 📄

Conclusion:

Dr. Felicia Antohe is an outstanding researcher whose work has greatly advanced our understanding of endothelial cell biology, molecular transport, and disease mechanisms. Her combination of technical expertise, leadership in multiple high-impact research projects, and numerous prestigious awards positions her as an ideal candidate for the Research for Molecular Cell Biology Award. While there is always room to expand her research applications, her contributions to science are already substantial and impactful.